Published in PLoS One on June 07, 2010
The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis (2011) 16.88
Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet (2010) 12.82
HIV incidence in men who have sex with men in England and Wales 2001-10: a nationwide population study. Lancet Infect Dis (2013) 3.10
Antiretroviral therapy in prevention of HIV and TB: update on current research efforts. Curr HIV Res (2011) 2.45
The Impact of Implementing a Test, Treat and Retain HIV Prevention Strategy in Atlanta among Black Men Who Have Sex with Men with a History of Incarceration: A Mathematical Model. PLoS One (2015) 1.46
Application and validation of case-finding algorithms for identifying individuals with human immunodeficiency virus from administrative data in British Columbia, Canada. PLoS One (2013) 1.09
HIV treatment as prevention: the key to an AIDS-free generation. J Food Drug Anal (2013) 1.05
Modelling the impact of antiretroviral therapy on the epidemic of HIV. Curr HIV Res (2011) 0.98
Process monitoring of an HIV treatment as prevention program in British Columbia, Canada. J Acquir Immune Defic Syndr (2014) 0.96
Mediators of antiretroviral adherence: a multisite international study. AIDS Care (2012) 0.94
HIV treatment for prevention. J Int AIDS Soc (2011) 0.93
Cohort profile: Seek and treat for the optimal prevention of HIV/AIDS in British Columbia (STOP HIV/AIDS BC). Int J Epidemiol (2014) 0.93
Assessing the effectiveness of antiretroviral regimens in cohort studies involving HIV-positive injection drug users. AIDS (2012) 0.92
High levels of heterogeneity in the HIV cascade of care across different population subgroups in British Columbia, Canada. PLoS One (2014) 0.87
Cohort Profile: HAART Observational Medical Evaluation and Research (HOMER) cohort. Int J Epidemiol (2014) 0.84
Mathematical models for the study of HIV spread and control amongst men who have sex with men. Eur J Epidemiol (2011) 0.84
A socio-ecological perspective of access to and acceptability of HIV/AIDS treatment and care services: a qualitative case study research. BMC Public Health (2016) 0.79
HIV stigma and the experiences of young men with voluntary and routine HIV testing. Sociol Health Illn (2015) 0.77
Prescription Opioid Injection Among HIV-Positive People Who Inject Drugs in a Canadian Setting. AIDS Behav (2016) 0.75
Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet (2008) 36.01
The global burden of typhoid fever. Bull World Health Organ (2004) 14.14
Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet (2009) 14.01
Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet (2008) 12.35
Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA (2008) 11.72
Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. Lancet (2006) 10.91
The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic. Lancet (2006) 7.17
Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study. BMJ (2009) 6.03
Impact of highly active antiretroviral treatment on HIV seroincidence among men who have sex with men: San Francisco. Am J Public Health (2002) 6.01
Effectiveness of highly active antiretroviral therapy in reducing heterosexual transmission of HIV. J Acquir Immune Defic Syndr (2005) 4.96
Decreased HIV transmission after a policy of providing free access to highly active antiretroviral therapy in Taiwan. J Infect Dis (2004) 4.17
British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med (2008) 3.67
Expanded access to highly active antiretroviral therapy: a potentially powerful strategy to curb the growth of the HIV epidemic. J Infect Dis (2008) 3.38
Improved virological outcomes in British Columbia concomitant with decreasing incidence of HIV type 1 drug resistance detection. Clin Infect Dis (2010) 3.12
Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy. AIDS (2007) 3.04
Male viral load and heterosexual transmission of HIV-1 subtype E in northern Thailand. J Acquir Immune Defic Syndr (2002) 2.48
The past, present, and future of HIV prevention: integrating behavioral, biomedical, and structural intervention strategies for the next generation of HIV prevention. Annu Rev Clin Psychol (2009) 2.39
Evolutionary dynamics of complex networks of HIV drug-resistant strains: the case of San Francisco. Science (2010) 2.19
Impact of neighborhood-level socioeconomic status on HIV disease progression in a universal health care setting. J Acquir Immune Defic Syndr (2008) 1.94
Potential impact of antiretroviral therapy on HIV-1 transmission and AIDS mortality in resource-limited settings. J Acquir Immune Defic Syndr (2006) 1.62
Challenges to HIV prevention--seeking effective measures in the absence of a vaccine. N Engl J Med (2008) 1.53
Can antiretroviral therapy eliminate HIV transmission? Lancet (2008) 1.53
Structural factors associated with an increased risk of HIV and sexually transmitted infection transmission among street-involved youth. BMC Public Health (2009) 1.31
HIV/AIDS in Vancouver, British Columbia: a growing epidemic. Harm Reduct J (2009) 1.24
Prioritising prevention strategies for patients in antiretroviral treatment programmes in resource-limited settings. AIDS Care (2010) 1.19
HIV-prevention science at a crossroads: advances in reducing sexual risk. Curr Opin HIV AIDS (2009) 1.18
The search for effective HIV vaccines. N Engl J Med (2005) 1.17
HIV prevalence among aboriginal British Columbians. Harm Reduct J (2005) 1.02
Population effect of scaling up ART in resource-poor settings. Lancet (2008) 1.02
Estimating vertically acquired HIV infections and the impact of the prevention of mother-to-child transmission program in Zimbabwe: insights from decision analysis models. J Acquir Immune Defic Syndr (2008) 1.02
The AIDS epidemic--a progress report from Mexico City. N Engl J Med (2008) 0.98
Treatment to prevent recurrent genital herpes. Curr Opin Infect Dis (2008) 0.84
Controlling the HIV epidemic, without a vaccine! AIDS (2008) 0.82
G8 funding for HIV universal access: a new opportunity for transparency. AIDS (2009) 0.80
Economic crisis threatens AIDS fight. AIDS Read (2009) 0.79
Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med (2009) 19.90
Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet (2002) 16.56
Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet (2009) 14.01
Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet (2010) 12.82
Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA (2008) 11.72
Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA (2010) 9.26
Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA (2006) 7.49
Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study. BMJ (2009) 6.03
Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med (2003) 5.79
Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA (2002) 5.56
Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up. AIDS (2002) 5.21
HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis. Lancet (2006) 5.00
Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. N Engl J Med (2002) 4.77
Life expectancy of persons receiving combination antiretroviral therapy in low-income countries: a cohort analysis from Uganda. Ann Intern Med (2011) 4.68
Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. J Infect Dis (2004) 4.55
The financial cost of doctors emigrating from sub-Saharan Africa: human capital analysis. BMJ (2011) 4.54
Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350 x 10(9) cells/L. Ann Intern Med (2003) 4.46
Risk factors for elevated HIV incidence among Aboriginal injection drug users in Vancouver. CMAJ (2003) 4.38
Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA (2004) 3.74
Late presentation for human immunodeficiency virus care in the United States and Canada. Clin Infect Dis (2010) 3.72
The combined effect of modern highly active antiretroviral therapy regimens and adherence on mortality over time. J Acquir Immune Defic Syndr (2009) 3.67
Changes in Canadian heroin supply coinciding with the Australian heroin shortage. Addiction (2006) 3.65
Evaluating methamphetamine use and risks of injection initiation among street youth: the ARYS study. Harm Reduct J (2006) 3.49
Cohort profile: the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). Int J Epidemiol (2007) 3.46
Expanded access to highly active antiretroviral therapy: a potentially powerful strategy to curb the growth of the HIV epidemic. J Infect Dis (2008) 3.38
Performance of immunologic responses in predicting viral load suppression: implications for monitoring patients in resource-limited settings. J Acquir Immune Defic Syndr (2006) 3.38
Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users. CMAJ (2003) 3.19
Reduction in overdose mortality after the opening of North America's first medically supervised safer injecting facility: a retrospective population-based study. Lancet (2011) 3.14
Improved virological outcomes in British Columbia concomitant with decreasing incidence of HIV type 1 drug resistance detection. Clin Infect Dis (2010) 3.12
The Canadian government's treatment of scientific process and evidence: inside the evaluation of North America's first supervised injecting facility. Int J Drug Policy (2008) 3.05
Estimated numbers of men and women infected with HIV/AIDS in Tijuana, Mexico. J Urban Health (2006) 3.04
Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy. AIDS (2007) 3.04
Opportunities for prevention: hepatitis C prevalence and incidence in a cohort of young injection drug users. Hepatology (2002) 2.99
Food insecurity is associated with incomplete HIV RNA suppression among homeless and marginally housed HIV-infected individuals in San Francisco. J Gen Intern Med (2008) 2.97
Does ratification of human-rights treaties have effects on population health? Lancet (2009) 2.93
Evidence of differential HLA class I-mediated viral evolution in functional and accessory/regulatory genes of HIV-1. PLoS Pathog (2007) 2.81
Invasive cervical cancer risk among HIV-infected women: a North American multicohort collaboration prospective study. J Acquir Immune Defic Syndr (2013) 2.78
Highly active antiretroviral therapy and survival in HIV-infected injection drug users. JAMA (2008) 2.77
Factors associated with persistent high-risk syringe sharing in the presence of an established needle exchange programme. AIDS (2002) 2.74
Discordant immunologic and virologic responses to highly active antiretroviral therapy are associated with increased mortality and poor adherence to therapy. J Acquir Immune Defic Syndr (2005) 2.74
Methadone maintenance therapy promotes initiation of antiretroviral therapy among injection drug users. Addiction (2010) 2.65
Displacement of Canada's largest public illicit drug market in response to a police crackdown. CMAJ (2004) 2.63
Changes in public order after the opening of a medically supervised safer injecting facility for illicit injection drug users. CMAJ (2004) 2.62
A simple, dynamic measure of antiretroviral therapy adherence predicts failure to maintain HIV-1 suppression. J Infect Dis (2006) 2.61
When to initiate antiretroviral therapy in HIV-1-infected adults: a review for clinicians and patients. Lancet Infect Dis (2005) 2.48
Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals. J Infect Dis (2005) 2.42
The effect of adherence on the association between depressive symptoms and mortality among HIV-infected individuals first initiating HAART. AIDS (2007) 2.39
Antiretroviral adherence and HIV treatment outcomes among HIV/HCV co-infected injection drug users: the role of methadone maintenance therapy. Drug Alcohol Depend (2006) 2.33
CD4+ T-cell count monitoring does not accurately identify HIV-infected adults with virologic failure receiving antiretroviral therapy. J Acquir Immune Defic Syndr (2008) 2.32
The association between food insecurity and mortality among HIV-infected individuals on HAART. J Acquir Immune Defic Syndr (2009) 2.31
A review of barriers and facilitators of HIV treatment among injection drug users. AIDS (2008) 2.21
U.S. trends in antiretroviral therapy use, HIV RNA plasma viral loads, and CD4 T-lymphocyte cell counts among HIV-infected persons, 2000 to 2008. Ann Intern Med (2012) 2.18
Impact of supply-side policies for control of illicit drugs in the face of the AIDS and overdose epidemics: investigation of a massive heroin seizure. CMAJ (2003) 2.18
Differential impact of adherence on long-term treatment response among naive HIV-infected individuals. AIDS (2008) 2.14
Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes. Antivir Ther (2004) 2.14
AIDS incidence and AIDS-related mortality in British Columbia, Canada, between 1981 and 2013: a retrospective study. Lancet HIV (2015) 2.09
A call for evidence-based medical treatment of opioid dependence in the United States and Canada. Health Aff (Millwood) (2013) 2.09
Food insecurity and hunger are prevalent among HIV-positive individuals in British Columbia, Canada. J Nutr (2005) 2.08
Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North America. Clin Infect Dis (2009) 2.05
Adverse effects of antiretroviral therapy for HIV infection. CMAJ (2004) 2.04
Expanding access to HAART: a cost-effective approach for treating and preventing HIV. AIDS (2010) 2.04
Willingness to participate and enroll in a phase 3 preventive HIV-1 vaccine trial. J Acquir Immune Defic Syndr (2002) 2.02
Validating a shortened depression scale (10 item CES-D) among HIV-positive people in British Columbia, Canada. PLoS One (2012) 2.02
Magnitude of virologic blips is associated with a higher risk for virologic rebound in HIV-infected individuals: a recurrent events analysis. J Infect Dis (2012) 2.00
Disease progression in patients with virological suppression in response to HAART is associated with the degree of immunological response. AIDS (2006) 1.98
Combination antiretroviral therapy in population affected by conflict: outcomes from large cohort in northern Uganda. BMJ (2009) 1.98
Childbearing intentions of HIV-positive women of reproductive age in Soweto, South Africa: the influence of expanding access to HAART in an HIV hyperendemic setting. Am J Public Health (2010) 1.95
Impact of neighborhood-level socioeconomic status on HIV disease progression in a universal health care setting. J Acquir Immune Defic Syndr (2008) 1.94
Increased resilience to the development of drug resistance with modern boosted protease inhibitor-based highly active antiretroviral therapy. J Infect Dis (2008) 1.93
Impact of baseline viral load and adherence on survival of HIV-infected adults with baseline CD4 cell counts > or = 200 cells/microl. AIDS (2006) 1.92